CCM
CLYM

CAAS Capital Management’s Climb Bio CLYM Stock Holding History

CAAS Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-75,000
Closed -$785K – 975
2021
Q4 		$785K Hold
75,000
– – 0.02% 476
2021
Q3 		$1.35M Buy
+75,000
New +$1.55M 0.03% 424

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CAAS Capital Management's CLYM Position: Q1 2022 in Review

CAAS Capital Management sold out of Climb Bio (CLYM) in Q1 2022, closing a stake of 75,000 shares — an estimated $785K sold.

CAAS Capital Management first reported a position in CLYM in Q3 2021 and held it in 2 quarters. The position peaked at $1.35M in Q3 2021. 43 funds tracked by Wall St. Rank hold CLYM as of Q1 2022.

  • CAAS Capital Management reported no remaining Climb Bio position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 75,000 Climb Bio shares in Q1 2022, an estimated $785K.
  • CAAS Capital Management first reported a position in Climb Bio in Q3 2021 and held it in 2 quarters.
  • CAAS Capital Management's Climb Bio position peaked at $1.35M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Climb Bio as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.